A fresh $1.5M in Series A funding is heading to Xeris Pharmaceuticals, Inc., a biopharmaceutical company focused on improving patient lives. The growth-oriented firm develops and commercializes advanced products across a range of therapies.

Get the full Xeris Pharmaceuticals, Inc. company profile
Access contacts, investors, buying signals & more
A fresh $1.5M in Series A funding is heading to Xeris Pharmaceuticals, Inc., a biopharmaceutical company focused on improving patient lives. The growth-oriented firm develops and commercializes advanced products across a range of therapies.
Portfolio company of VentureWell

xpander.ai
xpander.ai accelerates AI Agent development by allowing builders to focus on their agent logic, and easily get an AI Agent runtime environment, memory and state management, agentic tools, integrations with other AI Agents, various managed AI Agent triggering and chat options (Slack, MCP, A2A, Webhooks), all while supporting major AI Agent frameworks or any model that they wish to use, and iterate faster using a visual workbench.
$7.5M Seed
today

xpander.ai
xpander.ai accelerates AI Agent development by allowing builders to focus on their agent logic, and easily get an AI Agent runtime environment, memory and state management, agentic tools, integrations with other AI Agents, various managed AI Agent triggering and chat options (Slack, MCP, A2A, Webhooks), all while supporting major AI Agent frameworks or any model that they wish to use, and iterate faster using a visual workbench.
$7.5M Seed
today
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 | ![]() NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Takt United States | Series a | $9.3M | today |
| 2 | ![]() Gravis Robotics Switzerland | Series a | $200.0M | today |
| $7.2B |
| 1y ago |
| 3 | ![]() Illumina United States | Unknown | $7.1B | 1y ago |
| 4 | ![]() GRAIL United States | Unknown | $7.1B | 1y ago |
| 5 | ![]() RemeGen Biosciences United States | Grant | $5.6B | 7mo ago |
| 3 |
![]() Quartr Sweden |
| Series a |
| $18.0M |
| today |
| 4 | ![]() Amber Romania | Series a | $8.1M | today |
| 5 | ![]() Amber United Kingdom | Series a | $8.1M | today |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
See who invested in Xeris Pharmaceuticals, Inc. and reach their contacts directly.
Start free trialCarissa H.
Senior Director, Marketing Strategy
Mike M.
Regional Business Director, Rare Disease (Endocrinology)
Unlock 8 more key decision-makers at Xeris Pharmaceuticals, Inc. with verified emails and LinkedIn.
Start free trial
TuDOC
Recently received

Shyld AI
Recently received

Cardia, Inc.
Recently received